Takashima A, et al. - The ABSOLUTE trial demonstrated weekly nanoparticle albumin-bound paclitaxel (w-nab-PTX) as non-inferior to weekly solvent-based paclitaxel (w-sb-PTX) for overall survival (OS). Researchers sought for the predictive factors for efficacies of these agents. Among patients with peritoneal metastasis, the w-nab-PTX arm had longer OS than the w-sb-PTX arm, and median survival time (MST) of 9.9 and 8.7 months, respectively. Findings thus suggested the presence of apparent peritoneal metastasis as a predictive factor for selecting w-nab-PTX for pretreated advanced gastric cancer patients.